The 10th edition of PharmaLytica, organised by Informa Markets in India, commenced at HITEX, Hyderabad, focused on redefining the pharmaceutical industry in the post-COVID era. According to the organisers, the event saw participation of over 8,000 visitors and more than 200 exhibitors showcasing 1000+ brands.

Speaking on the occasion, Ravi Uday Bhaskar, Director General, Pharmaceuticals Export Promotion Council of India (Pharmexcil), said “During the pandemic and post-pandemic period, the Indian pharmaceutical industry made significant contributions. We exported US$ 27.8 billion worth of drugs in the financial year 2024, achieving a 9.6% growth rate despite numerous global challenges. We are expecting to reach more than US$ 31 billion in the next financial year. 50% of our exports are going to highly regulated markets. In North America and Europe, it's almost 55%. In the US, we exported more than 8 billion with a 15% growth rate, and to the UK, we achieved a 21% growth rate. This demonstrates the robust growth of the Indian pharmaceutical industry, even in challenging situations. As long as India continues to manufacture quality drugs at affordable prices, the industry will remain unmatched.”

Yogesh Mudras, Managing Director, Informa Markets in India said, “In 2024, the Indian pharmaceutical industry remains a global leader across the entire supply chain. It ranks third in production by volume and in terms of Active Pharmaceutical Ingredients (APIs) globally. With over 500 different APIs manufactured domestically, India contributes 57% of APIs to the WHO's prequalified list. The medical devices sector in India stands at a market size of US$ 11 billion. By 2032, the India analytical laboratory instruments market is projected to hit $4142.85 million, propelled by the government's focus on boosting production, notably supported by the flourishing pharmaceutical sector.”

Deepak Khurana, Vice President-Procurement & SCM, Suven Pharmaceuticals Limited said, The Indian pharmaceutical industry is experiencing significant growth and promising prospects. India leads in generic drug manufacturing and exports, meeting global demand for affordable medications. The emphasis on biopharmaceuticals and biosimilars is increasing, driven by their rising demand. The COVID-19 pandemic has accelerated digital health solutions and telemedicine adoption, transforming healthcare delivery. Regulatory reforms are set to boost innovation and quality. Indian pharmaceutical companies are ramping up R&D investments for novel drug discoveries. Expansion into emerging markets and a focus on specialty pharmaceuticals further fuel growth. Despite challenges like pricing pressures and regulatory complexities, the industry is poised for continued advancement.”